Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document


Previous Fragment    Next Fragment

Notice given 27 September 2006

2512  Senator Allison: To ask the Minister representing the Minister for Health and Ageing —With reference to the article in The Melbourne Age on 5 August 2006 ‘Big tobacco flicks cash at pub ban: How the cigarette company giants are funding clubland’s smoking fightback’:

(1) Is the Government aware of reports that hoteliers have been offered financial inducements by tobacco companies to finance open air venues and accommodate smokers once stricter indoor smoking bans are introduced in Victoria in 2007.

(2) Has the Government taken action to examine the legality of the above financial inducements; if so, what action has been taken.

(3) Has the Government taken action to explore measures to combat the moves by tobacco companies to impede the spirit of the indoor smoking bans; if so, what action has been taken.

2515  Senator Allison: To ask the Minister representing the Minister for Employment and Workplace Relations—

(1) How many young unemployed Australians have a learning disability.

(2) What programs are available to support these young people entering into full-time employment.

(3) (a) How many young people with a learning disability complete an employment readiness program; and (b) how many of these young people go onto full-time employment.

(4) What impact will the welfare to work legislation have on these young people.

(5) Is the Government monitoring the impact of the legislative changes on the quality of life of young people with a learning disability and their likelihood of entering full-time employment.

2516  Senator Allison: To ask the Minister representing the Minister for Health and Ageing—

(1) (a) Who can receive access to subsidised Rilutek as part of treatment for motor neurone disease; and (b) what limitations are placed on this access.

(2) Do these limitations include an age restriction; if so: (a) what is the justification for discriminating on the basis of age; and (b) what comparable medicines are available for people who do not meet the age criteria.

(3) Do criteria for access to subsidised Rilutek include length of illness; if so: (a) what is the justification for this; and (b) what comparable medicines are available for people who do not meet the length of illness criteria.

 

 (4) What steps has the Government taken to ensure that people under the age of 65 with motor neurone disease and who require levels of support that are currently only provided in residential aged care facilities are able to access that care outside of a residential aged care facility.